Look at why gene therapies for aging remain niche, focusing on delivery limitations and which targets fit current technologies.
Key Takeaways
- Of that large number, some are known to cause harm, and are associated with aspects of degenerative aging
- Gene therapy technology has existed for decades, but is not yet very broadly used
- Short answer is that gene therapy has a delivery problem